Gene Targeting and Gene Transfer Studies of the Biological Role of the Plasminogen/Plasmin System

Peter Carmeliet; Désiré Collen

doi:10.1055/s-0038-1642716

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1995; 74(01): 429-436
DOI: 10.1055/s-0038-1642716

Symposium

Plenary Lecture

Schattauer GmbH Stuttgart

Gene Targeting and Gene Transfer Studies of the Biological Role of the Plasminogen/Plasmin System

Peter Carmeliet

Center for Transgene Technology and Gene Therapy, Vlaams Interuniversitair Instituut voor Biotechnologie, Campus Gasthuisberg, Leuven, Belgium

,

Désiré Collen

Center for Transgene Technology and Gene Therapy, Vlaams Interuniversitair Instituut voor Biotechnologie, Campus Gasthuisberg, Leuven, Belgium

› Author Affiliations

Abstract

PDF Download

PDF (511 kb)

References

References
1 Astrup T. In: Progress in Chemical Fibrinolysis and Thrombolysis. Vol 3 . Davidson JF, Rowan RM, Samama MM, Desnoyers PC. eds. Raven Press; New Yorie: 1978: 1-57
2 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124
3 Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 801-804
4 Vassalli JD. The Urokinase Receptor. Fibrinolysis 1994; 8 (01) 172-181
5 Schneideiman J, Loskutoff DJ. Plasminogen activator inhibitors. Trends Cardiovasc Med 1991; 1: 99-102
6 Andreasen PA, Sottmp-Jensen LI. et al. Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Letters 1994; 338: 239-245
7 Richards WG, Carroll PM, KinlochR A, Wassarman PM, Strickland S. Creating maternal effect mutations in transgenic mice: antisense inhibition of an oocyte gene product. Develop Biol 1993; 160: 543-553
8 Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites HG, Marotti KR. Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346: 74-76
9 Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62: 447-456
10 Meiri N, Masos T, Rosenblum K, Miskin R, Dudai Y. Overexpression of urokinase-type plasminogen activator in transgenic mice is correlated with impaired learning. Proc Natl Acad Sci USA 1994; 91: 3196-3200
11 Sidenius N. Expression of the aminoteiminal fragment of urokinase-type plasminogen activator in transgenic mice. PhD.thesis. University of Copenhagen; Denmark: 1993
12 Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan R. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 419-424
13 Carmeliet P, De Clercq C, Janssen S, Pollefeyt S, Bouche A, Wijns S, Mulligan RC, Collen D. Biological effects of disruption of the tissue-type plasminogen activator, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci. (in press)
14 Carmeliet P, Kieckens L, Schoonjans L, Ream B, Van Nuffelen A, Prendergast G, Cole M, Bronson R, Collen D, Mulligan RC. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 1993; 92: 2746-2755
15 Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects cm hemostasis, thrombosis and thrombolysis. J Clin Invest 1993; 92: 2756-2760
16 Herz J, Clouthier DE, Hammer RE. LDL receptor-related protein internalizes and degrades uPA:PAI-l complexes and is essential for embryo implantation. Cell 1992; 71: 411-421
17 Umans L, Semeels L, Stas L, Overbergh L, Van Leuven F, Van den Berghe H. Targeted inactivation of the mouse alphaj-Macroglobulin gene results in a viable phenotype (submitted).
18 Dewerchin M, Carmeliet P, Van Nuffelen A, Collen D, and Mulligan RO M. Inactivation of the mouse urokinase receptor gene. Fibrinolysis 1994; 8 Suppl (Suppl. 01) A142
19 Ploplis V, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Stassen JM, Plow E, Collen D. Targeted inactivation of the murine plasminogen gene (Thrombosis and Haemostasis; this meeting).
20 Vassalli JD, Sappino JD, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-1072
21 Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Sem. Thromb Hemost 1987; 13: 50-68
22 Plow EF, Edgington TS. An alternative pathway for fibrinolysis. I. The cleavage of fibrinogen by leukocyte proteases at physiologic pH. J Clin Invest 1975; 56: 30-38
23 Hamsten A, de Faire U, Walldius G. et al. Plasminogen activator inhibitor in plasma:. risk factor for recurrent myocardial infarction.. Lancet 1987; 2: 3-9
24 Aoki N. Hemostasis associated with abnormalities of fibrinolysis. Blood Rev 1989; 3: 11-17
25 Carmeliet P, Stassen JM, Declercq C, Collen D. Arterial neointima formation in mice with inactivated plasminogen/plasmin system genes (submitted).
26 Carmeliet P, Stassen JM, Collen D, Meidell R, and Gerard R. Adenovirus- mediated gene transfer of rt-PA restores thrombolysis in t-PA deficient mice. Fibrinolysis 1994; 8 (01) A282
27 Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Complete deficiency of plasminogen-activator inhibitor type 1 due to a frameshift mutation. . N Engl J Med 1992; 327: 1729-1733
28 Elliott MJ, Faulkner-Jones BE, Stanton H, Hamilton JA, Metcalf D. Plasminogen activator in granulocyte-macrophage-CSF transgenic mice. J Immunol 1992; 149: 3678-3681
29 Clowes AW, Clowes MM, An Y PT, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-67
30 Jackson CL, Reidy MA. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann NY Acad Sci 1992; 667: 141-150
31 Sawa H, Sobel BE, Fujii S. Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury. Circ Res 1993; 73: 671-680
32 Herbert JM, Lamarche I, Prabonnaud V, Dol F, Gauthier T. Tissue-type plasminogen activator is a potent mitogen for human aortic smooth muscle cells. J Biol Chem 1994; 269: 3076-3080
33 Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991; 17: 758-769
34 Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991; 44: 139-143
35 Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK O. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb 1993; 13: 1090-1100
36 Sawa H, Fujii S, Sobel BE. Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis. Arterioscl Thromb 1992; 12: 1507-1515
37 Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet- derived growth factor in arterial smooth muscle cell migration after balloon catheter injury. Arterioscl Thromb 1993; 13: 1218-1226
38 Hamsten A, and Eriksson P. Fibrinolysis and Atherosclerosis: and update. Fibrinolysis 1994; 8 (01) 253-262
39 Juhan-Vague I, Collen D. On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 1992; 2: 427-438
40 Liu AC, and Lawn RM. Lipoprotein (a) and atherogenesis. Trends Cardiovasc Medicine 1994; 4: 40-44
41 Smokovitis A, Kokolis N, Alexaki-Tzivanidou E. Fatty streaks and fibrous plaques in human aorta show increased plasminogen activator activity. Haemostasis 1988; 18: 146-153
42 Underwood MJ, De Bono DP. Increased fibrinolytic activity in the intima of atheromatous coronary arteries: protection at a price. Cardiovasc Res 1993; 27: 882-885
43 Reilly JM, Sicard GA, Lucore CL. Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. J Vase Surg 1994; 19: 865-872
44 Grainger DJ, Kemp PR, Liu AC, Lawn RM, and Metcalfe JM. Activation of transforming growth factor-6 is inhibited in transgenic apolipoprotein (a) mice. Nature 1994; 370: 460-462
45 Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapoli W, Chapman HA. Depressed bronchioalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322: 890-897
46 Tomooka S, Border WA, Marshall BC, Noble NA. Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Internal 1992; 42: 1462-1469
47 Martin TJ, Allan EH, Fukumoto S. The plasminogen activator and inhibitor system in bone remodeling. Growth Regulation 1993; 3: 209-214
48 Leloup G, Lemoine P, Carmeliet P, Vaes G. Bone resorption and response to parathyroid hormone or 1,25 dihyroxyvitamin D3 in fetal metatarsals and calvariae from transgenic mice devoid of tissue or urokinase type plasminogen activator or of their inhibitor, PAI-l. Twenty fourth European Symposium on Calcified Tissues. 05/1995. Aarhus; Denmark: Calcified Tissue International (Abstract)
49 Bouillon R, Van Herck E, Verhaeghe J, Caimeliet P. Bone metabolism in transgenic mice, deficient in tissue type plasminogen activator. Xth International Congress on Calcium regulatory hormones. 02/1995. Melbourne; Australia: Bone and Mineral (Abstract)
50 Friedman GC, Seeds NW. Tissue plasminogen activator expression in the embryonic nervous system. Des Brain PS 1994; 81: 41-49
51 Sunni Y, Dent AR, Owen DE, Seeley PS, Morris RJ. The expression of tissue and urokinase plasminogen activator in neuronal development suggests different models of proteolytic involvement in neuronal growth. Development 1992; 116: 625-637
52 Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. issue-type plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993; 361: 453-457
53 Sappino AP, Madani R, Huarte J, Belin D, Kiss JZ, Wohlwend A, Vassalli JD. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993; 92: 679-685
54 Krystosek A, Seeds NW. Plasminogen activator release at the neuronal growth cone. Sciencez 1981; 213: 1532-1534
55 Carroll PM, Tsirka S, Richards WG, Frohman MA, Strickland S. Promoter sequences of the tissue-type plasminogen activator gene are able to confer tissue-specific expression of LacZ during mouse development (in press).
56 Theuring F, Aguzzi A, Turner JD, Kropp C, Wohn KD, Hoffmann S, Schleuning WD. Analysis of human tissue-type plasminogen activator gene promoter activity during embiyogenesis of transgenic mice and rats and its induction in the adult mouse brain (submitted).
57 Verrol S, Seeds NW. Characterization of l25I-tissue plasminogen activator binding to cerebellar granule neurons. J Cell Biol 1989; 109: 265-271
58 Kristensen P, Nielsen LS, Grpndahl-Jansen J, Andreasen PB, Larsson LI, Dano KI. J Cell Biol 1985; 101: 305-311
59 Dano K, Andreasen PA, Grondhal-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985; 44: 139-266
60 Pyke C, Kristensen P, Ralfkiaer E, Grondahl-Hansen J, Eriksen J, Blasi F, Dano K. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991; 138: 1059-1067
61 Duffy MJ. Plasminogen activators and cancer. Blood Coagulation Fibrinolysis 1991; 1: 681-687
62 Janicke F, Schmitt M, Graeff H. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer. Sem Thromb Hemostas 1991; 17: 303-312
63 Poggi A, Bellelli E, Carmela R, Castelli MP, Salvatore L, Marinacci R, Erickson LA, Benedetta Donati M, Bini A. Reduced pulmonary metastases of Lewis Lung Carcinoma in mice transgenic for the plasminogen activator inhibitor-1 gene (submitted).
64 Wagner EF. On trasferring genes into stem cells and mice. Embo J 1990; 9: 3024-3032
65 Botteri FM, Van der Putten H, Rajput B, Ballmer-Hofer K, Nagamine Y. Induction of the urokinase-type plasminogen activator gene by cytoskeleton- disrupting agents. In: Serine proteases and their serpin inhibitors in the nervous system.. Ed.: Festoff WB. Plenum Press; New York: 1990: 105-114
66 Declerck P, Carmeliet P, Verstreken M, De Cock F, Collen D. Monoclonal antibodies raised against the targeted proteins in gene-inactivated mice (submitted).